GENE ONLINE|News &
Opinion
Blog

Feature
The 8 Companies Propelling Taiwan’s Biopharma Industry
2021-10-21
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
2021-10-17
Reimagining the Healthcare System Innovation Ecosystem in Europe, Post-COVID
2021-10-21
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
On October 21st, Sio Gene Therapies Inc. made two major announcements featuring one of its lead gene therapy candidates. The New York-based company presented positive interim data for AXO-AAV-GM1, its AAV9-based gene therapy for GM1 gangliosidosis, at the ESGCT Virtual Congress 2021. On the same day, it also announced the FDA's Fast Track Designation granted for the drug.

GM1 gangliosidosis is a rare inherited disease with no FDA-approved treatments currently. Safety is a big concern in the field of AAV gene therapy and several promising endeavors have been shut down recently due to adverse events. However, AXO-AAV-GM1 has shown promising safety and efficacy in both the low-dose and high-dose cohorts.

"The results from the GM1 gangliosidosis program is one of the light bulb moments for me and I think this gene therapy could really make a difference," Pavan Cheruvu told GeneOnline. "With these important data in hand, we anticipate a meeting with the FDA in the first half of 2022 to discuss the next steps for clinical development for AXO-AAV-GM1."

2021-10-22
Expanding Deals and Investments Underscore Burgeoning Market of Targeted Protein Degradation
2021-10-07
Special
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
Even as we marvel at gut microbiome transplants as a major breakthrough in treating inflammatory bowel syndrome, there is a new arena for microbiome that is taking shape. Often called the largest organ of the human body, the human skin is host to more than 1,000 bacterial species. Apart from viruses, fungi, and archaea and there is a wide range of diseases that manifest here. Scientists at startups, as well as corporate houses, are now focusing their attention on developing microbiome-based treatments for the skin.

The skin is colonized by bacteria and other microbes since our birth and the hormonal changes that occur during puberty are responsible for acne, one of the commonest skin problems. Belgian company S-Biomedic is currently researching how to best use the skin microbiome to treat acne and is confident to release a consumer product in the next couple of years.

Besides acne, companies are also evaluating their skin microbiome products for body odor, atopic dermatitis, or psoriasis. Apart from biotech companies, cosmetic companies are also working on microbiome-based solutions with Loreal working to add anti-dandruff shampoo, anti-blemish, and probiotic enriched anti-aging sera to its product lines. At this pace, a day at the spa with microbiome-perfected products may not be very far.

2021-10-25
Reimagining the Healthcare System Innovation Ecosystem in Europe, Post-COVID
The COVID-19 pandemic transformed the pharma industry in the past two years, accelerating research and dialogue between stakeholders while unraveling significant deficiencies in the public healthcare infrastructure across the globe. At the tail-end of the pandemic, pioneers in healthcare took stock of the innovation, policies, and infrastructure at the Reuters event, Pharma 2021.

The first keynote panel discussion had industry experts look at the future of the healthcare innovation ecosystem in Europe. The panel comprised of 1. Nathalie Moll, Director General of EFPIA, European Federation of Pharmaceutical Industries and Associations 2. Jo De Cock, , Former Administrative General, INAMI, Institut national d'assurance maladie-invalidité, Belgium 3. Meindert Boysen, Director of National Institute of Health and Care Excellence, UK 4. Iskra Reic, Executive VP-AstraZeneca, Europe and Canada

Recounting their key learnings from the pandemic, the panelists shared optimism in incorporating collaboration and flexibility into building the future healthcare infrastructure.

2021-10-21
Scientists Identify Antidotes To Overcome Collateral Damage of Antibiotics on Gut Microbiota
Antibiotics fight life-threatening pathogens, but they could also kill commensal bacteria in the process. This disturbs the composition of gut microbiota, causing dysbiosis and disease.

Antibiotics developed to have broad-spectrum activities directly affect the gut microbiota, thereby compromising their multiple beneficial effects and weakening the body's first line of defense against pathogens. The most common side effects of this collateral damage are gastrointestinal problems and recurrent Clostridiodes difficle infections. This damage results in long-term health issues such as the development of allergic, metabolic, immunological, or inflammatory diseases.

Recently, EMBL researchers, along with their collaborators, analyzed the effects of 144 antibiotics on the most common gut microbes. The study published in Nature illuminates the activity spectra of antibiotics in commensal bacteria and suggests strategies to circumvent their adverse effects on the gut microbiota. This collaborative effort not only improves our understanding of the effects of antibiotics on gut microbes but also suggests a new approach to overcome them.

2021-10-20
LATEST
10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
2021-10-26
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
2021-10-25
Sanofi, Regeneron’s Dupixent Shines in Phase 3 Trial for Prurigo Nodularis
2021-10-25
ReCode Therapeutics Raises $80 Million in Series B to Advance Gene Therapy & LNP Delivery Platform
2021-10-23
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
2021-10-22
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
2021-10-22
Daiichi Sankyo to Launch mRNA Covid-19 Vaccine in 2022, Shionogi Presents Clinical Results of Covid-19 Oral Drug
2021-10-22
Deals
ShouTi Raises $100M in Series B to “Replace Biologic Injections with Pills”
2021-10-21
Axial Therapeutics to Advance Pipeline for Neurological Diseases with $37.25 Million Series C Funding
2021-10-17
858 Therapeutics Launches with $60 Million Series A for Advancing Small-Molecule Drugs
2021-09-23
Shanghai Startup Poised for $325M IPO on Nasdaq
2021-10-21
Oxford Nanopore Soars on London Market Debut
2021-10-05
Cue Health’s $200 Million Nasdaq IPO: Where Will the Ball Roll Next?
2021-09-27
M&A
Supernus Invests $400 Million to Acquire New Parkinson’s Assets from Adamas
2021-10-12
Pacira Acquires Flexion for $425 Million to Expand Non-Opioid Painkiller Portfolio
2021-10-12
Amicus Therapeutics Spins Off Its Gene Therapy Unit in a SPAC Deal
2021-10-02
Ranking & Reports
The 8 Companies Propelling Taiwan’s Biopharma Industry
2021-10-21
Taiwan’s Biotech Industry, Lackluster or Late Bloomer? A Breakdown of Policies, Hotspots, and Market Movements
2021-10-05
The 6 Companies Leading the Resurgence in RNA Editing R&D
2021-08-24
Categories
How Can Taiwan’s Biopharma Seize the Next Global Business Opportunity? – An Interview with Dr. Jerome Shen
2021-10-17
Revealing the Underestimated Potential of Natural RNA Editing – An Interview with Dr. Trees-Juen Chuang
2021-09-17
Current Challenges and Future Opportunities of Artificial RNA Editing – An Interview with Professor Toshifumi Tsukahara
2021-08-26
10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
2021-10-26
Daiichi Sankyo to Launch mRNA Covid-19 Vaccine in 2022, Shionogi Presents Clinical Results of Covid-19 Oral Drug
2021-10-22
The 8 Companies Propelling Taiwan’s Biopharma Industry
2021-10-21
Sanofi, Regeneron’s Dupixent Shines in Phase 3 Trial for Prurigo Nodularis
2021-10-25
Intellia’s CRISPR Drug Claims FDA Orphan Drug Designation to Treat ATTR Amyloidosis
2021-10-22
Sio Gene Therapies Touts Positive Safety and Biomarker Data for GM1 Gangliosidosis Candidate
2021-10-22
Shanghai Startup Poised for $325M IPO on Nasdaq
2021-10-21
Diabetes Care Device Maker Debuts On Hong Kong Exchange
2021-10-20
WuXi ATU Launches Fourth Manufacturing Site for Gene and Cell Therapy CTDMO Service
2021-10-19
What are Investors Looking for in a Biotech Startup?
2021-07-27
Primed to Surpass CRISPR: Prime Medicine Emerges Out of Stealth with $315 Million in Funding
2021-07-15
Blackstone Pumps $250 Million in CAR-T Startup, Betting on Intellia’s and Cellex’s Technologies
2021-06-23
10x Genomics Eyes Regional Opportunities in Asia-Pacific, Launches First Overseas Manufacturing Hub
2021-10-26
Canada Signs Deal with Moderna to Build Vaccine Plant in the Country
2021-08-12
Japan’s Kyowa Inks Deal with Taiwan’s CDMO Firm to Manufacture Generic Drugs
2021-08-06
Resilience, Harvard University Ink 5-Year Strategic R&D Alliance Leveraging Biomedical Innovation for a Resilient Tomorrow
2021-10-16
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2021-10-15
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
Could This Anti-Sperm Immunocontraception Work As a Novel Female Birth Control?
2021-08-24
New Study Explores How Sleep Deprivation Inhibits Memory Consolidation
2021-08-07
Kite to Invest in Next Generation Immunotherapy with Appia Bio Collaboration
2021-08-06
CYTENA Bioprocess Solutions Closes $5M Funding to Develop Automatic High-throughput Screening Platform for Pharmaceuticals
2021-10-05Partner
Taiwan’s AMS BioteQ Develops a New Antimicrobial Dressing Which Accelerates Diabetes Wound Healing
2021-09-22 Partner
Foundation Medicine Enters Partnership With Epic to Integrate Genomic Insights into EMR Systems
2021-08-30
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!